510(k) Summary

APR 0 2 2014

Submitted on behalf of:

Company Name: BK Meditech Co, Ltd Address: 215-5 Yodang-Li, Yanggam-Myun

Hwasung-Si, Kyunggi-Do Republic of Korea 445-931 Telephone: 82-313529135

Fax: 82-313529134

by: Elaine Duncan, M.S.M.E., RAC President, Paladin Medical, Inc. PO Box 560

Stillwater, MN 55082 Telephone: 715-549-6035

Fax: 715-549-5380

CONTACT PERSON: Elaine Duncan DATE PREPARED: March 3, 2014.

TRADE NAME: INNESIS PEEK CERVICAL CAGE

COMMON NAME: Intervertebral body fusion device

DEVICE CLASSIFICATION Class II

CLASSIFICATION NAME: Orthosis, Intervertebral body fusion device, cervical

REDUÁLTION: 888.3080 PRODUCT CODE: ODP

INDICATIONS FOR USE:

The INNESIS PEEK Cervical Cages are indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level (C2-T1). DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. INNESIS PEEK Cervical Cages are used to facilitate intervertebral body fusion in the cervical spine and are placed via an anterior approach and packed with autogenous bone. INNESIS PEEK Cervical Cages are to be used with supplemental fixation. Patients should have at least six (6) weeks of non-operative treatment prior to treatment with an intervertebral cage.

DESCRIPTION of the DEVICE:

The INNESIS PEEK Cervical Cage is an implant for the anterior stabilization of the cervical spinal column using an Anterior Cervical Desectomy and Fusion (ACDF) surgery. The INNESIS PEEK Cervical Cages are offered in a variety of heights, footprints and curved shapes. The INNESIS PEEK Cervical Cages have ridges or teeth that resist rotation and migration and have cavities to accept packing of bone graft. The INNESIS PEEK Cervical Cage includes spikes and marker (pin) for radiological evaluation of the position and orientation of the radiolucent PEEK Cage

SUBSTANTIALLY EQUIVALENCE DEMONSTRATED BY:

The subject and predicate devices are substantially equivalent in the areas of materials, design, indications for use and operational principles. Based on the comparison between the subject

and predicate devices, BK MEDITECH Co., Ltd. believes that the INNESIS PEEK Cervical Cages are substantially equivalent (as fully detailed in the submission) to predicate devices which include the following devices:

Company Name	Device Tradename	510(k)
		Number
BK MEDITECH Co., Ltd	INNESIS PEEK CAGE(lumbar)	K120464
Stryker Spine	Stryker Spine AVS® AS PEEK Spacer	K120486
Southern Spine, LLC	Southern Spine C-Fuse™ Cervical	K130948
	Intervertebral Body Fusion System	
SpineCraft, LLC	ORIO Intervertebral Body Fusion Cage by	K090887
Medacta International, SA	Mecta-C	K112862
Custom Spine	PATHWAY ACIF	K092904
Biomet Spine	C-Thru [™] Anterior Spinal System	K092336
BM Korea	SYNSTER® CERVICAL CAGE	K111820
Medicrea Technologies	IMPIX cervical interbody device	K072226

SUMMARY of TESTING:

Testing results are for the following:

- Static and dynamic axial compression test, conducted in accordance with ASTM F2077-03
- Static compression shear test, conducted in accordance with ASTM F2077-03
- Static and dynamic torsion test, conducted in accordance with ASTM F2077-03
- Static subsidence test, conducted in accordance with ASTM F2267-04
- Expulsion test, conducted in accordance with ASTM Draft Standard F04.25.02.02.

The material of the INNESIS PEEK Cervical Cage (permanent implant- long term) is PEEK (Polyetheretherketone, ASTM F2026) and Titanium Alloy (Ti6Al4V-ELI, ASTM F136). These materials are both recognized as suitable biomaterials for this intended use and predicate devices have previously been cleared by FDA for this same intended use. Endotoxin testing has demonstrated that the process does not introduce endotoxins as a bi-product of the manufacturing and cleaning process.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

April 2, 2014

BK Meditech Co., Ltd. % Elaine Duncan, M.S.M.E., RAC President Paladin Medical, Incorporated P.O. Box 560 Stillwater, Minnesota 55082

Re: K132483

Trade/Device Name: INNESIS PEEK Cervical Cage

Regulation Number: 21 CFR 888.3080

Regulation Name: Intervertebral body fusion device

Regulatory Class: Class II Product Code: ODP Dated: March 3, 2014 Received: March 4, 2014

Dear Ms. Duncan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

Page 2 - Elaine Duncan, MS.ME, RAC

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Ronald Palean - S for

Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

E40(la Marelane (if to a marelane)

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."